There is no dependence on antidepressants; however, discontinuation of such medications may cause a range of withdrawal reactions, including common symptoms such as dizziness, impaired balance, headache, nausea, insomnia, vivid dreams, and, in some patients, sensory numbness, hypersensitivity, depersonalization and irritability, and even hallucinations and hallucinations. Other researchers have classified the major SSRI withdrawal reactions into six categories: sensory symptoms, balance disorders, general somatic symptoms, affective symptoms, gastrointestinal symptoms, and sleep disturbances. Antidepressant discontinuation reactions can last 1-2 weeks and are usually mild, but there are instances where patients are severely distressed. It is generally believed that this condition is related to the elimination half-life of antidepressants: drugs with a short half-life are more likely to occur. Discontinuation reactions not only cause discomfort to the patient, but may be mistaken for a relapse, a physical illness, or a side effect of a new antidepressant, which can interfere with treatment. In particular, mothers-to-be, newborns and the elderly need to be aware of this. Understanding the pharmacological profile of different antidepressants can help explain discontinuation symptoms. Studies have shown that speed of discontinuation and duration of treatment are key predictors of antidepressant discontinuation response. For SSRIs, the 5-HTergic decline caused by abrupt discontinuation can lead to discontinuation symptoms, and the NE and DA systems may also be involved. In addition, some novel antidepressants, such as melatonin MT1/2 receptor agonists and the 5-HT receptor antagonist agomelatine, are largely free of withdrawal reactions, although they also have relatively short half-lives. This phenomenon also deserves to be explored. The biological mechanism of antidepressant withdrawal is still controversial; the basic consensus is that withdrawal symptoms can occur with any antidepressant, but are more common with TCAs, MAOIs, and SSRIs, especially those with higher potency and shorter half-life, such as paroxetine in SSRIs and venlafaxine in SNRIs.